The field of longevity therapeutics — with the goal “of not just adding years to life but adding life to years” — is already disrupting the medical industry, writes Marco Quarta.
Marco Quarta
Advertisement
Marco Quarta is CEO of Rubedo Life Sciences.
Articles by Marco Quarta
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
How are the Drug Pricing Negotiations Impacting Pharma's Relationship with DC?
2
Excellergy Announces Launch with $70 Million Series A Funding Aiming to Advance Pipeline of Trifunctional Effector Cell Response Inhibitors
3
Pharma Companies Shift Towards Direct-To-Consumer Sales in US Amidst Tariff and Pricing Turmoil
4
Policy Whiplash in Pharma: Navigating Volatility with Strategic Clarity
5
